Drug Profile
Research programme: metabolic disorders therapeutics - Gubra/Profil Institute
Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Gubra
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for research development in Diabetes-mellitus in Denmark
- 28 Aug 2019 No recent reports of development identified for research development in Non-alcoholic-fatty-liver-disease in Denmark
- 28 Aug 2019 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in Denmark